

Mylab receives approval for HPV RT-PCR test for cervical cancer detection

28 September 2022 | News

Test has high accuracy and sensitivity, and is suitable for mass screening with complete automation platforms

Human papillomaviruses (HPV) is responsible for more than 95% of cervical cancer. Molecular tests for detection of HPV play a crucial role in the prevention of cervical cancer. Continuing with its commitment to introduce high-quality diagnostics, Pune-based startup Mylab Discovery Solutions has launched 'PathoDetect HPV Detection Test', a real-time PCR based screening solution to detect high-risk types of HPV in individuals.

Approved by regulatory authority, 'PathoDetect HPV Detection Test' detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.

One of the important benefits of this test is that a woman with a positive (High Risk HPV) cervical screening result may be advised for further follow-up tests at shorter intervals. A negative test for the high-risk HPV genotypes would mean a longer interval between the next screening test.

Mylab also plans to introduce an extension of this kit which can simultaneously detect up to 15 high-risk along with discrimination of HPV 16 & 18 covering more than 95% cases of cervical cancers.

Speaking about the launch of 'PathoDetect HPV Detection Test', Hasmukh Rawal, Cofounder & Managing Director of Mylab said, "Cervical cancer is preventable; hence, with effective screening, early diagnosis of HPV and timely intervention by Gynecologists, it can often be treated successfully."

The test allows high throughput testing that is accurate, automated, simple, and reliable with Mylab Compact platform series automations within 2 hours without any high-end infrastructure or technical expertise requirements.